Skip to main content
Clinical Trials/NCT02111655
NCT02111655
Completed
Not Applicable

Second Generation Surveillance Techniques to Prevent Thrombosis and Increase Assisted Primary Patency in Native Arteriovenous Fistula. A Prospective Controlled Trial.

Hospital Infanta Sofia5 sites in 1 country212 target enrollmentSeptember 1, 2012
ConditionsThrombosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Thrombosis
Sponsor
Hospital Infanta Sofia
Enrollment
212
Locations
5
Primary Endpoint
Improved primary patency rate in arteriovenous fistulae with the use of doppler ultrasound and transonic dilution method
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

All vascular access guidelines recommend monitoring and surveillance protocols to prevent vascular access complications in hemodialysis units.

However, in the case of second generation screening techniques which determine access blood flow measurement (QA), there is a huge controversy about it´s efficiency.

Although multiple observational studies find a decrease in the thrombosis rate and an increased primary assisted patency survival related to the use of these techniques, a recently published meta-analysis find contradictory results in the randomized controlled trials, affirming that the measurement of QA is useless in grafts and questionable in native arteriovenous fistulae (AVF).

We have designed a multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the QA measurement using two complementary second generation techniques, Doppler ultrasound and Transonic dilution method, compared to the classical monitoring and surveillance methods.

The primary endpoint will be a reduction in the thrombosis rate with an increased assisted primary patency survival, and a cost effectiveness economic analysis.

As secondary endpoints we will analyze the impact over non-assisted primary patency survival and secondary patency survival.

Detailed Description

Definition: Multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the QA measurement using two complementary second generation techniques, Doppler ultrasound and Transonic dilution method, compared to the classical monitoring and surveillance methods. For Patient Registries: Clinical data repository (CDR) paper notebook will contain all baseline patient characteristics and the information related to vascular access. These data will be collected by the different investigators and reviewed and included in data base by the study´s monitor. This information will be included in a centralized computer database (SPSS 15.0 computer system) and encoded in order to preserve patients´ confidentiality.

Registry
clinicaltrials.gov
Start Date
September 1, 2012
End Date
September 29, 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hospital Infanta Sofia
Responsible Party
Principal Investigator
Principal Investigator

Antonio Cirugeda

Principal Investigator

Hospital Infanta Sofia

Eligibility Criteria

Inclusion Criteria

  • Informed consent signature.
  • Age between 18 and 95 years old.
  • Functioning native AVF.
  • Patients with end stage renal disease (ESRD) undergoing hemodialysis program for at least three months.

Exclusion Criteria

  • Coagulopathy or hemoglobinopathy of any cause.
  • Hospitalization of any cause in the previous month.
  • VA related complications or dysfunction in the previous three months.

Outcomes

Primary Outcomes

Improved primary patency rate in arteriovenous fistulae with the use of doppler ultrasound and transonic dilution method

Time Frame: Up to 3 years follow up

Differences in assisted primary patency rates (thrombosis free access survival) in AVF between the two groups: control group in which classical monitoring and surveillance techniques are applied and experimental group in which Doppler ultrasound and transonic were performed every three months in addition to classical methods. Cost efficacy analysis in both groups will be done, measuring all vascular access (VA) related health care spending (VA hospitalization costs, central venous catheter (CVC) placements, surgeries and endovascular procedures will be recorded).

Secondary Outcomes

  • Compared non-assisted primary patency rates (intervention free access survival) and secondary patency rates (access survival until abandonment) between the two groups.(Up to 3 years follow up)
  • Possible influence of different baseline items in the risk of thrombosis of native AVF(Up to 3 years follow up)
  • Reproducibility in Doppler ultrasound technique(Up to 3 years follow up.)
  • Evaluate the efficacy and efficiency of second generation methods(Up to 3 years follow up)

Study Sites (5)

Loading locations...

Similar Trials